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A 69-year-old male had initially presented with low-grade proteinuria, microhema-
turia, and a positive myeloperoxidase anti-neutrophilic antibody (ANCA). He subse-
quently developed deterioration of kidney function and developed uremic symptoms.
Creatinine was 486.2μmol/L (5.5mg/dL). Anti-MPO was positive (titer >8U, normal
<0.4). He was clinically diagnosed with rapidly proliferative glomerulonephritis most
likely due to ANCA vasculitis. He received three doses of pulse methylprednisolone
therapy. Kidney biopsy showed pauci-immune glomerulonephritis. Immunofluorescence
was positive for faint linear IgG staining of glomerular basement membrane (GBM).
Anti-GBM antibody was positive 2.1U (normal <1). He was started on high-dose
oral steroids; monthly intravenous cyclophosphamide and plasmapheresis were also
initiated. His symptoms improved and creatinine is 247.5μmol/L (2.8mg/dL). His
repeat anti-GBM antibody was negative. This is a rare case of rapidly progres-
sive glomerulonephritis due to dual MPO-ANCA antibodies and anti-GBM antibodies
(DAV).
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Introduction
Vasculitis secondary to the combination of anti-glomerular basement membrane (GBM) anti-
body and ANCA is rare. Depending upon the series studied, the incidence is 0.47–0.55 per
million people per year (1). Several other studies have also studied the association between
ANCA and anti-GBM antibodies. Depending upon the series between 5 and 14% of patients with
primarily ANCA vasculitis also were found to have anti-GBM antibodies and between 30 and
38% of patients with anti-GBM disease also had ANCA antibodies (2, 3). Light microscopy in
patients with DAV cannot be differentiated from patients who had ANCA or anti-GBM vasculitis
alone (4).
In this case report, we present a case of rapidly proliferative glomerulonephritis (RPGN) who had
DAV who responded to treatment.
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FIGURE 1 | Crescents on light microscopy.
Case Summary
This is a 69-year-old male with a history of diabetes mellitus,
hypertension, and no history of kidney disease was referred to
the nephrologist for evaluation of microscopic hematuria, pro-
teinuria, and borderline elevated creatinine. He previously had
a negative cystoscopy. He was asymptomatic on presentation.
His home medicines included metoprolol, enalapril, simvastatin,
metformin, and aspirin. His initial work-up revealed creatinine of
117.57μmol/L (1.33mg/dL). UA was positive for RBC and pro-
tein. Urine protein/creatinine ratio was 728mg/g. MPO-ANCA
was positive >8U (Normal <0.4). Proteinase 3b and ANA were
negative. Serum complements were normal; hepatitis panel was
negative. Kidney biopsy was advised but he refused. He agreed
to monthly follow-up, but was non-compliant with his follow-
up. He presented to ER after 3months with vomiting, weak-
ness, and decreased urine output. Creatinine was 461.44μmol/L
(5.22mg/dL) and his urine showed RBC, RBC cast, and was
positive for protein. It was felt that he likely had RPGN secondary
to ANCA vasculitis. He was hospitalized and intravenous fluid
was initiated. Aspirin and metformin were held. He was given
kayexalate and was given 1 g of pulse methypredinisolone therapy
daily for 3 days. He had a kidney biopsy, which showed diffuse
necrotizing, sclerosing, and primarily pauci-immune crescentic
glomerulonephritis (Figure 1). There were no changes of dia-
betic nephropathy. Immunofluorescence also revealed faint linear
staining of GBM for IgG (Figure 2). Due to linear GBM staining
anti-GBM antibody was sent, which was positive (2.1). Three
doses of pulse methylprednisolone therapy were followed by oral
prednisone 100mg po daily and intravenous cyclophosphamide
was initiated. A tunneled catheter was placed and he had five
plasma exchanges over 2weeks. Themost recent serum creatinine
was 2.0mg/dL. Repeat anti-GBM antibody was negative.
Discussion
Circulating ANCA and anti-GBM are both associated with
rapidly proliferative glomerulonephritis. Both are rare diseases.
FIGURE 2 | Immunofluorescence linear staining of IgG.
ANCA is usually present in older patients with prevalence of
2.5/100,000. Anti-GBM disease is still rarer with prevalence of
0.5–0.9/1,000,000 (5). Asmentioned before, the incidence of DAV
is rarer but still can occur up to 14% in patients with primarily
ANCA and in up to 38% of patients with primarily anti-GBM
disease (3). ANCA vasculitis is a very complex disorder, which
has been linked to infections, silica, mercury, lead, and drugs like
propylthiouracil, allopurinol, and hydralazine. Most cases, how-
ever, are idiopathic (6). ANCA antibodies can attach to antigens
present with in neutrophil granules, causing degranulation of the
neutrophils thus causing damage due cytotoxic oxygen free radical
species, so ANCA antibodies are thus not only a marker of the
disease butmay also be directly pathogenic (7). The target for anti-
GBM antibody is alpha 3 chain of type 4 collagen on GBM and
alveoli (5). Renal involvement in both type of vasculitis is usually
crescentic necrotizing glomerulonephritis. Immunofluorescence
in anti-GBM disease reveals very distinct strong linear basement
IgG staining of GBM, while in ANCA vasculitis immunofluo-
rescence is negative (2, 5). In this case, immunofluorescence of
kidney biopsy specimen revealed only faint linear deposit of IgG
on the GBM.
There are important clinical implications of having dual anti-
body positive as opposed to only one in terms of clinical presen-
tation, prognosis, relapse, and treatment.
Systemic complaints are common in ANCA vasculitis (8). In
anti-GBM antibody disease, systemic symptoms are very rare
and usually present with end organ involvement like pulmonary
hemorrhage and RPGN. Thus, when anti-GBM disease patients
have systemic symptoms earlier in the course, it may indicate that
patient may have concurrent DAV (9).
Relapse is not uncommon in ANCA vasculitis and can occur
in 17% of cases. Relapse mostly occurs in 12–18months after the
initial remission. Anti-GBM antibody rarely recurs since antibody
production is short lived. Relapse with DAV is higher than in
anti-GBM disease (9).
Prognosis in DAV may be intermediate between isolated
ANCA diseases and isolated anti-GBM disease. Prognosis in pure
ANCA vasculitis has better prognosis compared to the other two.
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In one study, 75% of patients on dialysis due to pure ANCA-
related disease recovered function with appropriate treatment
(10). Bosch et al. showed that 45% of patients on dialysis due to
DAV recovered significant renal function with treatment. None
of the anti-GBM disease patients on dialysis was able to come
off dialysis (11). The best predictor of outcome in anti-GBM
disease is the severity of glomerular injury, creatinine at presenta-
tion, and titer of anti-GBM antibody (9). Rutgers et al., however,
found DAV prognosis more similar to anti-GBM disease alone.
He reported that dialysis dependency at admission was 28% in
MPO–ANCA positive patients, 60% in DAV, and 69% with anti-
GBM disease patients. Cumulative renal survival at 1 year was
64% for MPO–ANCA vasculitis, 10% for DAV, and 15% for anti-
GBM disease. None of their patients on dialysis recovered kidney
function (4). Levy et al. noted that patients with DAV had poor
response to therapy and their prognosis was similar to patients
with pure anti-GBM disease inspite of receiving plasmapheresis
in addition to immunosuppression (12).
Treatment of vasculitis due to ANCA antibody is cyclophos-
phamide or rituximab and steroids (13). Plasmapheresis is some-
times added when renal failure is severe or rapidly progress-
ing (14). Treatment of anti-GBM disease is plasmapheresis,
cyclophosphamide, and steroids. Treatment of DAV is the same
as in anti-GBM disease (12).
There were some atypical features of this case that are worth
emphasizing. Systemic ANCA vasculitis typically presents with
constitutional symptoms, such as fever, malaise, arthralgia, and
weight loss. Prodromal symptoms can last for a few months
before the involvement of a specific organ (15). In a study of
70 patients with ANCA vasculitis, isolated renal vasculitis was
noted in 25% of patients. Patients with isolated renal vasculi-
tis had advanced glomerulosclerosis as they did not have any
constitutional symptoms and presented late in the course of the
disease (8). Our patient presented to us early in the course of
his disease, with minimally elevated creatinine, microhematuria,
and proteinuria without any constitutional symptoms and only
later developed uremic symptoms when kidney function deteri-
orated. As this patient initially presented with minimal disease,
one could have attributed this to diabetic kidney disease, and
argued that checking ANCA initially in a patient without RPGN
and no symptoms was unnecessary. Studies have shown that
microhematuria can be seen in up to 30% of patients with diabetic
nephropathy (16). However, a Japanese study in 154 patients with
diabetes mellitus found that 7% of patients with microhematuria
had glomerular diseases other than diabetic nephropathy. Also,
patients who had diabetic nephropathy and microhematuria were
more likely to have advanced diffuse, nodular, exudative, and
interstitial lesions than those in the non-hematuria group (17).
So the presence of microhematuria in a diabetic patient even
without a typical presentation of vasculitis-like RPGN should trig-
ger workup for non-diabetic glomerulopathy, such as vasculitis,
especially if the patient is not known to have established diabetic
nephropathy.
Furthermore, immunofluorescence microscopy in this patient
showed very faint linear IgG staining of the GBM, which is not
typical of anti-GBM disease. Immunofluorescence microscopy in
anti-GBM disease typically shows very dense, strong staining of
GBM (2). Faint linear staining of GBM can be a feature of diabetic
nephropathy. Our patient was diabetic, but there were no other
features of diabetic nephropathy on the biopsy. It is rare to have
linear staining due to diabetes in the absence of light microscopy
evidence of diabetic nephropathy (18). Thus, the presence of any
linear staining of GBM in the setting of glomerulonephritis, in
the absence of light microscopy evidence of diabetic nephropathy,
should suggest the presence of anti-GBM disease.
Conclusion
Patients who have either ANCA related disease or anti-GBM-
related disease should be tested for other antibodies as both these
antibodies are sometimes present together. Presentation, treat-
ment, and prognosis of dual antibody vasculitis may be different
from isolated ANCA related vasculitis. Isolated renal vasculitis
should be considered in an asymptomatic patient who presents
with proteinuria and microhematuria. Also, even faint linear
staining without the presence of diabetic nephropathy can suggest
anti-GBM disease.
Author’s Note
Consent has been obtained from the patient for publication of this
case report.
References
1. DE Zoysa J, Taylor D, Thein H, Yehia M. Incidence and features of dual
anti-GBM-positive and ANCA-positive patients. Nephrology (Carlton) (2011)
16(8):725–9. doi:10.1111/j.1440-1797.2011.01484.x
2. Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM
and neutrophil cytoplasm in rapidly progressive glomerulonephritis.Kidney Int
(1990) 37(3):965–70. doi:10.1038/ki.1990.72
3. Hellmark T, Niles JL, Collins AB, McCluskey RT, Brunmark C. Comparison of
anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol (1997)
8(3):376–85.
4. Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Ter-
vaert JW. Coexistence of anti-glomerular basement membrane antibodies and
myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis
(2005) 46(2):253–62. doi:10.1053/j.ajkd.2005.05.003
5. Lindic J, Vizjak A, Ferluga D, Kovac D, Ales A, Kveder R, et al. Clinical
outcome of patients with coexistent antineutrophil cytoplasmic antibodies and
antibodies against glomerular basement membrane. Ther Apher Dial (2009)
13(4):278–81. doi:10.1111/j.1744-9987.2009.00724.x
6. Cooper DS. Antithyroid drugs. N Engl J Med (2005) 352(9):905–17. doi:10.
1056/NEJMra042972
7. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic
autoantibodies induce neutrophils to degranulate and produce oxygen radicals
in vitro. Proc Natl Acad Sci U S A (1990) 87(11):4115–9. doi:10.1073/pnas.87.
11.4115
8. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil
cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculi-
tis. The Glomerular Disease Collaborative Network. Ann Intern Med (1990)
113(9):656–63. doi:10.7326/0003-4819-113-9-656
9. Jennette JC, Olson JL, Schwartz MM, Silva FG. Glomerulonephritis and good-
pasture’s syndrome. Heptinstall’s Pathology of the Kidney. 6th ed. Philadelphia,
PA: Lippincott Williams &Wilkins (2006). p. 613–42.
10. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J,
et al. A randomized trial of maintenance therapy for vasculitis associated with
Frontiers in Medicine | www.frontiersin.org August 2015 | Volume 2 | Article 533
Mavani et al. Dual antibody vasculitis
antineutrophil cytoplasmic autoantibodies. N Engl J Med (2003) 349(1):36–44.
doi:10.1056/NEJMoa020286
11. Bosch X, Mirapeix E, Font J, Borrellas X, Rodríguez R, López-Soto A, et al.
Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with
myeloperoxidase specificity in anti-glomerular basement membrane disease.
Clin Nephrol (1991) 36(3):107–13.
12. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular
basement membrane antibody disease treated with plasma exchange and
immunosuppression. Ann Intern Med (2001) 134(11):1033–42. doi:10.7326/
0003-4819-134-11-200106050-00009
13. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy
of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med
(2013) 369(5):417–27. doi:10.1056/NEJMoa1213277
14. Pepper RJ, Chanouzas D, Tarzi R, Little MA, Casian A, Walsh M, et al. Intra-
venous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-
associated vasculitis. Clin J Am Soc Nephrol (2013) 8(2):219–24. doi:10.2215/
CJN.03680412
15. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med (1997)
337(21):1512–23. doi:10.1056/NEJM199711203372106
16. O’Neill WM Jr, Wallin JD, Walker PD. Hematuria and red cell casts in typi-
cal diabetic nephropathy. Am J Med (1983) 74(3):389–95. doi:10.1016/0002-
9343(83)90956-7
17. Matsumura N, Hanatani M, Nishino T, Ishihara K, Kishimoto T, Tonomura
Y, et al. The clinico-pathological significance of hematuria in diabetics. Nihon
Jinzo Gakkai Shi (1994) 36(9):1036–45.
18. Burns AP, Fisher M, Li P, Pusey CD, Rees AJ. Molecular analysis of HLA class
II genes in Goodpasture’s disease. QJM (1995) 88(2):93.
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Mavani, Pommier, Win, Michelis and Rosenstock. This is an open-
access article distributed under the terms of the Creative CommonsAttribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Medicine | www.frontiersin.org August 2015 | Volume 2 | Article 534
